Since the time cytoplasmic NACHT-LRRPYD-containing protein-3 (NLRP) 3 inflammasome was first identified and its activation by MSU and CPP crystals was demonstrated (Martinon et al., 2006), interleukin (IL)-1β has been considered the most important inflammatory mediator in crystal-induced inflammation, and it represents one of the main targets for new drugs that have been or are being developed to treat gout and calcium crystal-induced arthritis (Dinarello, 2014). The gene discussed is IL1B; the disease is gout.